Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822318 | 0.83 | HSD11B1 (0.38) | EPHX2HSD11B1HSD11B2 | |
| SCHEMBL2822315 | 0.83 | HSD11B1 (0.38) | EPHX2HSD11B1HSD11B2 | |
| SCHEMBL2827173 | 0.75 | P2RX7 (0.32) | LMNAPOLBKMT2A | |
| SCHEMBL2822321 | 0.75 | P2RX7 (0.35) | LMNAPOLBKMT2A | |
| SCHEMBL6325458 | 0.71 | HSD11B1 (0.57) | EPHX2HSD11B1HSD11B2LMNA | |
| SCHEMBL12308304 | 0.71 | HSD11B1 (0.60) | EPHX2HSD11B1HSD11B2 | |
| SCHEMBL12057044 | 0.71 | SMN1; SMN2 (0.46) | EPHX2HSD11B1HSD11B2LMNAPOLB | |
| SCHEMBL12057046 | 0.71 | SMN1; SMN2 (0.46) | EPHX2HSD11B1HSD11B2LMNAPOLB | |
| SCHEMBL233166 | 0.71 | HSD11B1 (0.68) | HSD11B1HSD11B2REN | |
| SCHEMBL2823435 | 0.70 | HSD11B1 (0.43) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | claimed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | claimed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | claimed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | claimed |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2012-01-05 | — | — | US | claimed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | claimed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | claimed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | claimed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | claimed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | claimed |
| US-9464072-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2015-04-09 | — | — | US | disclosed |
| US-8940902-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | EPHX2 1935/4885HSD11B1 5/4885HSD11B2 14/4885 |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | EPHX2 643/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | EPHX2 527/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | EPHX2 527/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | EPHX2 643/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | EPHX2 1935/4885HSD11B1 5/4885HSD11B2 14/4885 |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | EPHX2 1935/4885HSD11B1 5/4885HSD11B2 14/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | EPHX2 661/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | EPHX2 643/4885HSD11B1 1/4885HSD11B2 3/4885 |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | EPHX2 1935/4885HSD11B1 5/4885HSD11B2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.